[go: up one dir, main page]

SG11201706041XA - Methods and compositions for inducing hematopoietic cell differentiation - Google Patents

Methods and compositions for inducing hematopoietic cell differentiation

Info

Publication number
SG11201706041XA
SG11201706041XA SG11201706041XA SG11201706041XA SG11201706041XA SG 11201706041X A SG11201706041X A SG 11201706041XA SG 11201706041X A SG11201706041X A SG 11201706041XA SG 11201706041X A SG11201706041X A SG 11201706041XA SG 11201706041X A SG11201706041X A SG 11201706041XA
Authority
SG
Singapore
Prior art keywords
compositions
methods
cell differentiation
hematopoietic cell
inducing hematopoietic
Prior art date
Application number
SG11201706041XA
Inventor
Bahram Valamehr
Raedun Clarke
Original Assignee
Fate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fate Therapeutics Inc filed Critical Fate Therapeutics Inc
Publication of SG11201706041XA publication Critical patent/SG11201706041XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/14—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2303—Interleukin-3 (IL-3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2311—Interleukin-11 (IL-11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1369—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from blood-borne mesenchymal stem cells, e.g. MSC from umbilical blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
SG11201706041XA 2015-01-26 2016-01-26 Methods and compositions for inducing hematopoietic cell differentiation SG11201706041XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562107517P 2015-01-26 2015-01-26
US201562251016P 2015-11-04 2015-11-04
PCT/US2016/014918 WO2016123100A1 (en) 2015-01-26 2016-01-26 Methods and compositions for inducing hematopoietic cell differentiation

Publications (1)

Publication Number Publication Date
SG11201706041XA true SG11201706041XA (en) 2017-08-30

Family

ID=56544232

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201706041XA SG11201706041XA (en) 2015-01-26 2016-01-26 Methods and compositions for inducing hematopoietic cell differentiation
SG10202101358XA SG10202101358XA (en) 2015-01-26 2016-01-26 Methods and compositions for inducing hematopoietic cell differentiation

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202101358XA SG10202101358XA (en) 2015-01-26 2016-01-26 Methods and compositions for inducing hematopoietic cell differentiation

Country Status (7)

Country Link
US (4) US10626372B1 (en)
EP (1) EP3250680A4 (en)
JP (5) JP6800859B2 (en)
CN (2) CN114058582A (en)
AU (3) AU2016211671B2 (en)
SG (2) SG11201706041XA (en)
WO (1) WO2016123100A1 (en)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9763984B2 (en) 2012-12-21 2017-09-19 Astellas Institute For Regenerative Medicine Methods for production of platelets from pluripotent stem cells and compositions thereof
JP6800859B2 (en) 2015-01-26 2020-12-16 フェイト セラピューティクス，インコーポレイテッド Methods and Compositions for Inducing Hematopoietic Cell Differentiation
MX2018000897A (en) 2015-07-21 2018-11-09 The Children´S Medical Center Corp Pd-l1 expressing hematopoietic stem cells and uses.
CA3002157A1 (en) * 2015-10-20 2017-04-27 FUJIFILM Cellular Dynamics, Inc. Methods for directed differentiation of pluripotent stem cells to immune cells
KR20250033315A (en) 2015-11-04 2025-03-07 페이트 세러퓨틱스, 인코포레이티드 Methods and compositions for inducing hematopoietic cell differentiation
AU2016349504B2 (en) 2015-11-04 2023-02-09 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
SG11201805186VA (en) 2016-01-20 2018-07-30 Fate Therapeutics Inc Compositions and methods for immune cell modulation in adoptive immunotherapies
US11413309B2 (en) 2016-01-20 2022-08-16 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
EP3510145A4 (en) 2016-09-06 2020-03-25 The Children's Medical Center Corporation IMMUNE CELLS DERIVED FROM INDUCED PLURIPOTENT STEM CELLS
WO2018106595A1 (en) 2016-12-05 2018-06-14 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
CN110691844B (en) * 2017-02-07 2023-09-08 新加坡科技研究局 Methods and kits for generating simulated innate immune cells from pluripotent stem cells
EP3589293A4 (en) * 2017-02-28 2020-12-16 The Regents of the University of California DIFFERENTIATION AND USE OF HUMAN MICROGLIA-LIKE CELLS FROM PLURIPOTENT STEM CELLS AND HEMATOPOIETIC ANALYZER CELLS
EP3601532B1 (en) 2017-03-27 2025-04-23 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to obtain lymphoid progenitors
MX2019011897A (en) 2017-04-18 2019-11-28 Fujifilm Cellular Dynamics Inc Antigen-specific immune effector cells.
CA3068604A1 (en) 2017-06-13 2018-12-20 Fate Therapeutics, Inc. Compositions and methods for inducing myeloid suppressive cells and use thereof
EP3654986A2 (en) 2017-07-19 2020-05-27 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
CN107488629A (en) * 2017-08-14 2017-12-19 中国科学院广州生物医药与健康研究院 A kind of directed differentiation method of human pluripotent stem cells
WO2019060708A1 (en) 2017-09-22 2019-03-28 The Children's Medical Center Corporation Treatment of type 1 diabetes and autoimmune diseases or disorders
WO2019131941A1 (en) * 2017-12-28 2019-07-04 株式会社カネカ Cell aggregation inhibitor
EP3740566A4 (en) * 2018-01-18 2021-10-27 Agency for Science, Technology and Research METHOD OF DIFFERENTIATING HUMAN PLURIPOTENT STEM CELL LINES IN A SUSPENSION CULTURE
CN108300695B (en) * 2018-02-07 2021-08-06 清华大学 A method for differentiating human pluripotent stem cells into hematopoietic stem cells and culture additives
KR20200121817A (en) * 2018-02-14 2020-10-26 서니브룩 리서치 인스티튜트 Methods for generating cells of the T cell lineage
FR3079239A1 (en) * 2018-03-23 2019-09-27 Centre National De La Recherche Scientifique NOVEL METHOD OF OBTAINING T CELLS FROM PLURIPOTENT STEM CELLS AND USES THEREOF
US12497593B2 (en) 2018-09-07 2025-12-16 Wisconsin Alumni Research Foundation Generation of hematopoietic progenitor cells from human pluripotent stem cells
CN109182251A (en) * 2018-10-08 2019-01-11 吉林大学 A kind of low blood serum medium expanding endothelial progenitor cells quantity
US20220025330A1 (en) * 2019-01-22 2022-01-27 Washington University Compositions and methods for generating hematopoietic stem cells (hscs)
CN111607566B (en) * 2019-02-22 2023-04-14 安徽中盛溯源生物科技有限公司 Method and application of differentiating human pluripotent stem cells into hematopoietic progenitor cells
CN109652369B (en) * 2019-02-28 2020-01-03 西湖生物医药科技(杭州)有限公司 Method for preparing mature red blood cells in vitro by using peripheral blood and preparation
CN110106146B (en) * 2019-03-28 2021-04-02 中国人民解放军军事科学院军事医学研究院 Application of compound ketotifen fumarate in promotion of synthesis and secretion of stem cell factors
JP2022526983A (en) * 2019-04-03 2022-05-27 アクロン・バイオテクノロジー・リミテッド・ライアビリティ・カンパニー Cryopreservation and cell culture medium
EP3952891A4 (en) * 2019-04-09 2023-01-25 Rutgers, the State University of New Jersey METHODS FOR ENCOURAGEMENT OF CELL POPULATIONS
CN110025014A (en) * 2019-04-18 2019-07-19 宝康士(中国)保健食品销售有限公司 The method of substrate liquid of the hybrid bacterial strain fermentation preparation rich in probiotics and NK cell
US11453862B2 (en) 2019-07-08 2022-09-27 Immunitybio, Inc. Mononuclear cell derived NK cells
GB201911957D0 (en) * 2019-08-20 2019-10-02 Adaptimmune Ltd Methods of producing haemogenic progenitor cells from pluripotent stem cells
JP2022545415A (en) * 2019-08-20 2022-10-27 アダプティミューン・リミテッド Culture medium for hematopoiesis induction
CN115003800A (en) * 2019-08-28 2022-09-02 安斯泰来再生医药协会 Methods of treating vascular disorders
WO2021116362A1 (en) * 2019-12-11 2021-06-17 Repairon Gmbh Expansion of stem cells in suspension in a bioreactor
US11788065B2 (en) 2019-12-23 2023-10-17 Boston Medical Center Corporation Human iPSC-based derivation of NK and T-cells using early Notch induction
IL295964A (en) 2020-02-28 2022-10-01 Takeda Pharmaceuticals Co Method for producing natural killer cells from pluripotent stem cells
EP4110900A4 (en) * 2020-02-28 2024-04-24 Purdue Research Foundation Generating aorta-gonad-mesonephros-like hematopoietic cells from human pluripotent stem cells under a defined condition
CA3176416A1 (en) * 2020-04-21 2021-10-28 Modassir CHOUDHRY Cellular vaccine platform and methods of use
CN111808812B (en) * 2020-08-31 2020-12-15 首都医科大学附属北京友谊医院 A material and method for the differentiation of pluripotent stem cells into hematopoietic stem cells
WO2022113056A1 (en) 2020-11-30 2022-06-02 Crispr Therapeutics Ag Gene-edited natural killer cells
US11473060B2 (en) 2020-12-30 2022-10-18 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into NK cells
US20240043800A1 (en) * 2021-02-05 2024-02-08 Sungkwang Medical Foundation Method for differentiating pluripotent stem cell-derived hemogenic endothelial cells into lymphoid lineage cells
GB202102297D0 (en) * 2021-02-18 2021-04-07 Adaptimmune Ltd Methods of Producing Haemogenic Endothelial Cells from Pluripotent Stem Cells
JP2024512327A (en) * 2021-03-05 2024-03-19 ザ チルドレンズ メディカル センター コーポレーション Stroma-free NK cell differentiation method from human pluripotent stem cells
CA3214216A1 (en) * 2021-03-31 2022-10-06 Dhvanit Shah Pluripotent stem cell-derived hematopoietic lineages
DE112022000079T5 (en) 2021-04-01 2023-06-15 Hayk Davtyan Genetic modification of mammalian cells to confer resistance to CSF1R antagonists
CN113215086A (en) * 2021-05-26 2021-08-06 杭州原生生物科技有限公司 Culture medium and method for induced differentiation of pluripotent stem cells into hematopoietic stem cells
BR112023026141A2 (en) * 2021-06-15 2024-03-05 Takeda Pharmaceuticals Co METHODS FOR PRODUCING A CELL POPULATION ENRICHED IN NK CELLS, FOR PRODUCING NK CELLS DERIVED FROM INDUCED PLURIPOTENT STEM CELLS, FOR TREATING A SUBJECT IN NEED OF CELL THERAPY, AND FOR PRODUCING A CELL POPULATION COMPRISING HEMA PROGENITOR CELLS CD34+ TOPOIETICS, AND, POPULATIONS OF NK CELLS AND UNCLASSIFIED CELLS
EP4373920A1 (en) * 2021-07-19 2024-05-29 Repairon Immuno GmbH Method of producing a population of immune cells from pluripotent stem cells
KR102595504B1 (en) * 2021-10-13 2023-10-30 랩인큐브 주식회사 Nanoplatform capable of differentiation of stem cells and manufacturing method thereof
CA3242986A1 (en) 2021-12-17 2023-06-22 Umoja Biopharma, Inc. Cytotoxic innate lymphoid cell and uses thereof
WO2023138680A1 (en) * 2022-01-20 2023-07-27 科济生物医药（上海）有限公司 Method for inducing cell differentiation
WO2023156774A1 (en) * 2022-02-15 2023-08-24 The University Of Birmingham Generating bone marrow organoids
EP4506449A1 (en) * 2022-04-01 2025-02-12 Therabest Co., Ltd. Natural killer cells produced from induced pluripotent stem cells, method for producing same, and use thereof
CN114752548B (en) * 2022-04-28 2025-01-21 澳门大学 A method for inducing stem cells to differentiate into keratinocytes
CN114774365B (en) * 2022-06-16 2022-08-23 呈诺再生医学科技(北京)有限公司 A method for inducing iPSC differentiation to obtain CD34+ cells and NK cells and its application
CN114958771B (en) * 2022-06-27 2023-12-05 广东康盾创新产业集团股份公司 Preparation method of IPSC-CAR-NK cells
US20240067932A1 (en) * 2022-08-25 2024-02-29 Trailhead Biosystems Inc. Methods and compositions for generating hemogenic endothelial cells from pluripotent stem cells
JP2025531268A (en) 2022-09-19 2025-09-19 チューン セラピューティクス インコーポレイテッド Compositions, systems, and methods for modulating T cell function
WO2024175080A1 (en) 2023-02-24 2024-08-29 士泽生物医药（苏州）有限公司 Kit for inducing stem cells to differentiate into nk cells, use of kit, and use of combination of nk cells and tmz in treatment for tmz drug-resistant gbm
WO2025029840A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for multiplexed activation and repression of t cell gene expression
WO2025029835A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for modulating il-2 gene expression
WO2025125560A1 (en) * 2023-12-15 2025-06-19 Institut National de la Santé et de la Recherche Médicale Methods for generating myeloid cells
CN117757625A (en) * 2023-12-20 2024-03-26 中国医学科学院输血研究所 Method for inducing NK cells based on a porous material
WO2025219552A1 (en) * 2024-04-17 2025-10-23 Assitance Publique Hopitaux De Paris Method for producing t cell progenitors from human pluripotent stem cells
GB202405750D0 (en) * 2024-04-24 2024-06-05 Plasticell Ltd Therapy

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US5780300A (en) 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
CA2292339A1 (en) 1997-06-13 1998-12-17 Ludwig Institute For Cancer Research Smad6 and uses thereof
IL132840A (en) 1997-07-01 2004-12-15 Warner Lambert Co 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and pharmaceutical compositions comprising them for use as mek inhibitors
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
ES2302726T3 (en) 2000-02-24 2008-08-01 Invitrogen Corporation STIMULATION AND SIMULTANEOUS CONCENTRATION OF CELLS.
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
HU230251B1 (en) 2000-07-19 2015-11-30 Warner-Lambert Co. Ester derivatives of 4-iodo phenylamino benzhydroxamic acids and pharmaceutical compositions containing them
JP2002060786A (en) 2000-08-23 2002-02-26 Kao Corp Bactericidal antifouling agent for hard surfaces
US6689744B2 (en) 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses
WO2002059285A1 (en) 2000-10-27 2002-08-01 Fred Hutchinson Cancer Research Center Methods for immortalizing cells
WO2003016496A2 (en) 2001-08-20 2003-02-27 The Scripps Research Institute Zinc finger binding domains for cnn
PT1456380E (en) 2001-11-02 2012-07-23 Giuliani Int Ltd Smad7 inhibitors for the treatment of cns diseases
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
SI2275102T1 (en) 2002-03-13 2015-12-31 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US7575925B2 (en) 2002-12-10 2009-08-18 Sunnybrook Health Sciences Centre Cell preparations comprising cells of the T cell lineage and methods of making and using them
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
EP2251327B1 (en) 2003-11-19 2014-02-12 Array Biopharma, Inc. Heterocyclic inhibitors of mek
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
WO2005118788A2 (en) 2004-05-27 2005-12-15 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
US20070036769A9 (en) 2004-06-03 2007-02-15 Linheng Li BMP pathway methods and compositions
EP2361905B1 (en) 2005-05-18 2013-03-06 Array Biopharma Inc. Heterocyclic Inhibitors of MEK and methods of use thereof
EP1992360A4 (en) 2006-02-01 2010-02-17 Univ Tokyo USE IN ASSOCIATION OF A TGF-BETA SIGNAL INHIBITOR AND ANTITUMMER AGENT
EP1999255A2 (en) 2006-03-24 2008-12-10 The Children's Medical Center Corporation Method to modulate hematopoietic stem cell growth
EP2044056B1 (en) 2006-07-14 2012-08-22 Novartis AG Pyrimidine derivatives as alk-5 inhibitors
CA2676044C (en) 2007-01-30 2019-10-22 University Of Georgia Research Foundation, Inc. Early mesoderm cells, a stable population of mesendoderm cells that has utility for generation of endoderm and mesoderm lineages and multipotent migratory cells (mmc)
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
WO2009097140A1 (en) 2008-01-30 2009-08-06 Memorial Sloan-Kettering Cancer Center Methods for off -the -shelf tumor immunotherapy using allogeneic t-cell precursors
WO2009104825A1 (en) * 2008-02-18 2009-08-27 Kaist Method for inducing the defferentiation of embryonic stem cells into hemangioblast
CA2722693C (en) 2008-05-06 2023-03-21 Advanced Cell Technology, Inc. Hemangio colony forming cells and non-engrafting hemangio cells
CA2995883C (en) 2008-12-03 2023-01-24 The Scripps Research Institute Compounds and methods for stabilizing cell cultures
WO2010087594A2 (en) 2009-01-28 2010-08-05 한국생명공학연구원 Cd93 or use of soluble fragment thereof
US8557580B2 (en) * 2009-02-20 2013-10-15 Cellular Dynamics International, Inc. Methods and compositions for the differentiation of stem cells
US8372642B2 (en) * 2009-02-27 2013-02-12 Cellular Dynamics International, Inc. Differentiation of pluripotent cells
EP2419511B1 (en) 2009-04-09 2018-01-17 Sangamo Therapeutics, Inc. Targeted integration into stem cells
US9005968B2 (en) 2009-10-16 2015-04-14 The Scripps Research Institute Induction of pluripotent cells
TR201815882T4 (en) 2009-12-10 2018-11-21 Univ Iowa State Res Found Inc Tal effector mediated DNA modification.
WO2011096482A1 (en) * 2010-02-03 2011-08-11 国立大学法人東京大学 Method for reconstructing immune system using pluripotent stem cells
US9206394B2 (en) 2010-02-03 2015-12-08 The University Of Tokyo Method for reconstructing immune function using pluripotent stem cells
EP2547764B1 (en) 2010-03-18 2019-01-23 Kyoto University Method for inducing differentiation of pluripotent stem cells into mesodermal cells
EP2580320B1 (en) 2010-06-14 2018-08-01 The Scripps Research Institute Reprogramming of cells to a new fate
JP5984217B2 (en) * 2010-06-15 2016-09-06 セルラー ダイナミクス インターナショナル， インコーポレイテッド Preparation of induced pluripotent stem cells from a small amount of peripheral blood
EP2596011B1 (en) 2010-07-21 2018-10-03 Sangamo Therapeutics, Inc. Methods and compositions for modification of a hla locus
CN108531444A (en) 2010-08-05 2018-09-14 威斯康星校友研究基金会 Simplification basal medium for people's pluripotent cell culture
CN106214701B (en) 2010-08-12 2020-09-25 菲特治疗公司 Improved hematopoietic stem and progenitor cell therapy
US9181529B2 (en) * 2010-10-19 2015-11-10 Cellular Dynamics International, Inc. Titration of differentiation medium components
WO2012087962A2 (en) 2010-12-20 2012-06-28 Genentech, Inc. Anti-mesothelin antibodies and immunoconjugates
KR101975688B1 (en) * 2010-12-22 2019-05-07 페이트 세러퓨틱스, 인코포레이티드 Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
EA028902B1 (en) 2010-12-31 2018-01-31 Университет Фюр Боденкультур Вена Method of generating induced pluripotent stem cells and differentiated cells
US8700106B2 (en) 2011-03-09 2014-04-15 Universal Electronics Inc. System and method for provision of infrared signalling in smart phone devices
CN102732483B (en) 2011-03-31 2014-12-03 北京大学 Preparation method for hematopoietic progenitor cells and special medium for same
US20130071414A1 (en) 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
EP2732029B1 (en) 2011-07-11 2019-01-16 FUJIFILM Cellular Dynamics, Inc. Methods for cell reprogramming and genome engineering
EP2745840B1 (en) 2011-08-16 2017-07-12 Samsung Life Public Welfare Foundation Composition including stem cell-derived microvesicles for use in promoting neurogenesis
CN102329769B (en) 2011-09-28 2013-07-31 浙江大学 Method for obtaining hematopoietic stem cells
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
JP6344821B2 (en) 2011-11-21 2018-06-20 ユニバーシティ・ヘルス・ネットワーク A population of hematopoietic progenitors and a method of enriching stem cells for hematopoietic progenitors
PT2785834T (en) 2011-12-02 2020-11-13 Fate Therapeutics Inc Enhanced stem cell composition
EP2788475A1 (en) 2011-12-05 2014-10-15 Primorigen Biosciences Inc. Compositions and methods for differentiating pluripotent stem cells into primitive blood cells and uses thereof
EP2788476B1 (en) 2011-12-08 2019-05-22 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
EP2606884A1 (en) 2011-12-21 2013-06-26 Ecole Polytechnique Fédérale de Lausanne (EPFL) Inhibitors of notch signaling pathway and use thereof in treatment of cancers
SG10201606959PA (en) 2012-02-24 2016-09-29 Hutchinson Fred Cancer Res Compositions and methods for the treatment of hemoglobinopathies
CA3085032A1 (en) 2012-04-17 2013-10-24 University Of Washington Through Its Center For Commercialization Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof
DK2839013T3 (en) 2012-04-18 2020-09-14 Univ Leland Stanford Junior NON-DISRUPTIVE-GEN-TARGETING
US9260696B2 (en) * 2012-04-24 2016-02-16 Dan S. Kaufman Method for developing natural killer cells from stem cells
WO2013176197A1 (en) 2012-05-22 2013-11-28 国立大学法人 東京大学 Method for producing antigen-specific t cells
WO2013176915A1 (en) 2012-05-25 2013-11-28 Roman Galetto Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
WO2014011540A1 (en) 2012-07-09 2014-01-16 Emory University Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto
NZ746914A (en) 2012-10-02 2020-03-27 Memorial Sloan Kettering Cancer Center Compositions and methods for immunotherapy
CN104995294A (en) 2012-10-19 2015-10-21 新加坡科技研究局 Methods of differentiating stem cells into one or more cell lineages
US9382531B2 (en) 2012-10-22 2016-07-05 Wisconsin Alumni Research Foundation Induction of hemogenic endothelium from pluripotent stem cells
AU2013355327A1 (en) 2012-12-05 2015-06-11 Sangamo Therapeutics, Inc. Methods and compositions for regulation of metabolic disorders
US9763984B2 (en) 2012-12-21 2017-09-19 Astellas Institute For Regenerative Medicine Methods for production of platelets from pluripotent stem cells and compositions thereof
US9938499B2 (en) * 2013-03-13 2018-04-10 Wisconsin Alumni Research Foundation Methods and materials for hematoendothelial differentiation of human pluripotent stem cells under defined conditions
KR102466666B1 (en) 2013-03-15 2022-11-15 메모리얼 슬로안 케터링 캔서 센터 Compositions and methods for immunotherapy
US9943545B2 (en) 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
CA2908668C (en) 2013-04-03 2023-03-14 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted t cells derived from pluripotent stem cells
CN115261411A (en) 2013-04-04 2022-11-01 哈佛学院校长同事会 Therapeutic uses of genome editing with CRISPR/Cas systems
CA2926078C (en) 2013-10-17 2021-11-16 Sangamo Biosciences, Inc. Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
US9932607B2 (en) 2013-11-15 2018-04-03 The Board Of Trustees Of The Leland Stanford Junior University Site-specific integration of transgenes into human cells
WO2015134652A1 (en) 2014-03-04 2015-09-11 Bahram Valamehr Improved reprogramming methods and cell culture platforms
CN106715467B (en) 2014-03-28 2021-07-27 明尼苏达大学评议会 Polypeptides, cells and methods involving engineered CD16
CA2945393C (en) 2014-04-24 2021-03-23 Board Of Regents, The University Of Texas System Application of induced pluripotent stem cells to generate adoptive cell therapy products
CN103937743B (en) 2014-04-27 2017-12-01 浙江大学 A kind of method that candidate stem cell is obtained using three-dimensional inducible system
JP2018504122A (en) 2015-01-26 2018-02-15 フェイト セラピューティクス，インコーポレイテッド Cells with increased immunomodulatory properties and methods for their use and production
JP6800859B2 (en) 2015-01-26 2020-12-16 フェイト セラピューティクス，インコーポレイテッド Methods and Compositions for Inducing Hematopoietic Cell Differentiation
US20170020922A1 (en) 2015-07-16 2017-01-26 Batu Biologics Inc. Gene editing for immunological destruction of neoplasia
EP3756682B8 (en) 2015-10-05 2022-04-27 Precision Biosciences, Inc. Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene
AU2016349504B2 (en) 2015-11-04 2023-02-09 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
KR20250033315A (en) 2015-11-04 2025-03-07 페이트 세러퓨틱스, 인코포레이티드 Methods and compositions for inducing hematopoietic cell differentiation
WO2017164257A1 (en) 2016-03-23 2017-09-28 国立大学法人京都大学 Mesoderm induction method having high blood cell differentiation capacity
PT4180519T (en) 2016-04-15 2025-09-04 Memorial Sloan Kettering Cancer Center Transgenic t cell and chimeric antigen receptor t cell compositions and related methods

Also Published As

Publication number Publication date
JP6836803B2 (en) 2021-03-03
JP2018502591A (en) 2018-02-01
JP2021058223A (en) 2021-04-15
JP2019103521A (en) 2019-06-27
US11634688B2 (en) 2023-04-25
AU2016211671A1 (en) 2017-08-10
AU2016211671B2 (en) 2022-05-26
CN107429230B (en) 2021-11-12
JP2023058748A (en) 2023-04-25
EP3250680A4 (en) 2018-12-05
JP6800859B2 (en) 2020-12-16
US20180072992A1 (en) 2018-03-15
CN114058582A (en) 2022-02-18
HK1247245A1 (en) 2018-09-21
SG10202101358XA (en) 2021-03-30
WO2016123100A1 (en) 2016-08-04
JP7720337B2 (en) 2025-08-07
US20200248142A1 (en) 2020-08-06
AU2022203153B2 (en) 2024-10-03
AU2022203153A1 (en) 2022-06-02
US20230212518A1 (en) 2023-07-06
CA2974381A1 (en) 2016-08-04
EP3250680A1 (en) 2017-12-06
US10626372B1 (en) 2020-04-21
CN107429230A (en) 2017-12-01
AU2024287257A1 (en) 2025-01-23
JP7236476B2 (en) 2023-03-09
US12385012B2 (en) 2025-08-12
JP2025078772A (en) 2025-05-20

Similar Documents

Publication Publication Date Title
SG11201803145RA (en) Methods and compositions for inducing hematopoietic cell differentiation
SG11201706041XA (en) Methods and compositions for inducing hematopoietic cell differentiation
IL259576A (en) Compositions and methods for immunooncology
IL259321A (en) Compositions and methods for enhanced gene expression in cone cells
IL259084A (en) Methods and compositions for gene editing in hematopoietic stem cells
ZA201900225B (en) Methods and compositions for gene expression in plants
GB2546350B (en) Compositions and methods
IL251951A0 (en) Methods and compositions for natural killer cells
IL251576A0 (en) Methods and compositions for generating or maintaining pluripotent cells
EP3212225A4 (en) Methods and compositions for modified t cells
GB201718876D0 (en) Antithrombin-heparin compositions and methods
IL246879B (en) Apilimod compositions and methods for using same
SI3766582T1 (en) Cell culture
KR101819190B9 (en) Composition for destructing microalgae
GB201512996D0 (en) Compositions and methods
GB201401373D0 (en) Compositions for cells lysis and uses thereof
SG11201801873TA (en) Process and compositions for achieving mammalian energy balance
EP3230440A4 (en) Compositions and methods for neuronal differentiation of cells
HK1260760A1 (en) Methods and compositions for inducing hematopoietic cell differentiation
GB201514413D0 (en) Compositions and methods
IL256261B (en) Hide1 compositions and methods
AU2014904953A0 (en) Compositions and methods for neuronal differentiation of cells
GB201522554D0 (en) Methods and compositions
GB201518167D0 (en) Methods and compositions
GB201514415D0 (en) Compositions and methods